Welcome to the clinical data market

A primer on the players, revenue models, and issues in today's clinical data market—including a brief discussion of the potential effect of synthetic data on the clinical data market.

Amanda Berra
Amanda Berra
14 min read

A primer to establish what’s what before tackling the next-level question: What will the advent of synthetic data do to the clinical data market?

Having researched corporate innovation at health systems, I know system leaders have long been interested in figuring out ways to monetize clinical data. It makes sense: if systems could manage to sell or license de-identified data in their EHRs to life science or tech companies, that would be very helpful from a revenue diversification perspective. Especially whenever core inpatient economics are under siege.

But, it’s always been an easier-said-than-done proposition. And NOW, maybe there’s also a new spoiler in the mix, in the form of ‘synthetic data’. Synthetic data = AI-created, de-identified, no-patient-privacy-risk datasets that have the same statistical characteristics as actual clinical datasets.

Let’s talk.

Questions? Want to learn more about what Union can do for you? We’d love to hear from you.